Eli Lilly to acquire Hypnion

LLY will acquire neurology company Hypnion (Lexington, Mass.) for an undisclosed amount of cash. Hypnion's oral HY10275 is in Phase II testing to treat insomnia by improving both sleep induction and maintenance. In January, Phase II data showed the selective histamine H1 and serotonin (5-HT2A) receptor modulator met the primary endpoint of a reduction in wake after sleep onset (WASO) (See BioCentury, Jan. 15, 2007). ...